Preview

Current Pediatrics

Advanced search

EXPERIENCE OF TREATMENT OF THE TWINS SICK WITH JUVENILE IDIOPATHIC ARTHRITIS BY ABATACEPT

https://doi.org/10.15690/vsp.v13i3.1036

Abstract

The case of clinical observation over twin brothers (boys E. and N) suffering juvenile idiopathic arthritis is presented in the article. Boys fell ill with a difference in 1 year and 5 months at the age of 1 year and 9 months and 3 years 2 months, respectively. The disease proceeded wavily with the periods of remissions and exacerbations. Resistant articulate syndrome developed in July and November, 2009, respectively. Both children received NSAID, methotrexate combination in a dose of 10 mg/m2/week and sulphasalazine in a dose of 20 mg/kg of body weight per day. To the boy E. it was also prescripted prednisolon in a dose of 10 mg per day. Duration of antirheumatic therapy made 7 and 3 months, respectively. The therapy with a blocker of T-lymphocytes costimulation, abatacept, was initiated for the twins due to the inefficiency of treatment by immunodepressants and prednisolon at the boy E. In 6 weeks of the treatment 50% improvement, in 24 weeks — 90% improvement by criteria of the American College of Rheumatologists (ACRpedi) were registered. The undesirable phenomena weren’t observed.

About the Author

V. A. Kel'tsev
Samara State Medical University
Russian Federation
Kel’tsev Vladimir Alekseevich, PhD, professor, Head of the Department of Theoretical Pediatrics


References

1. Texbook of paediatric rheumatology, 5th Edn. J. Cassidy, R. Petty (eds). Philadelphia: Elsevier Saunders. 2005. 541 с.

2. Kel’tsev V. A. Klinicheskaya artrologiya. Ruk-vo dlya vrachei, prepodavatelei, nauch. sotr [Clinical Arthrology. Guideline for Doctors, Tutors, Research Scientists]. Samara, 2010. 616 p.

3. Woo R., Southwood T. R., Prieur A. M. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43 (8): 1849–1857.

4. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.

5. Nasonov E. L. RMZh — Russian medical journal. 2009; 17 (3): 2–7.

6. Davies R., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.

7. Linsley P. S., Brady W., Urnes M., Genant H. K. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.

8. Webb L. M., Walmsley M. J., Feldmаnn M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7–1 and B7–2. Eur. J. Immunol. 1996; 26: 2320–2328.


Review

For citations:


Kel'tsev V.A. EXPERIENCE OF TREATMENT OF THE TWINS SICK WITH JUVENILE IDIOPATHIC ARTHRITIS BY ABATACEPT. Current Pediatrics. 2014;13(3):104-109. (In Russ.) https://doi.org/10.15690/vsp.v13i3.1036

Views: 813


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)